Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DDI Study of TEV-56286 (anle138b) in Healthy Volunteers
NCT05532358Phase 1Completed
- Sponsor
- MODAG
- Start
- Sep 2022
- Primary completion
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of emrusolmin in multiple system atrophy (MSA) and Parkinson's disease (PD) (2 arms), sponsored by MODAG. Primary endpoints: Oral pharmacokinetics (PK) of caffeine administered without TEV-56286 at Day 1, Oral pharmacokinetics (PK) of midazolam administered without TEV-56286 at Day 1 and 6 more. Started Sep 2022; status: completed.
02
Drugs
emrusolmin
03
Conditions
multiple system atrophy (MSA)Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT05532358.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05532358.